[HTML][HTML] Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control

ME Youssef, G Yahya, MS Popoviciu, S Cavalu… - International Journal of …, 2023 - mdpi.com
The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …

[HTML][HTML] Alzheimer's disease: a clinical practice-oriented review

L Alves, ASA Correia, R Miguel, P Alegria… - Frontiers in …, 2012 - frontiersin.org
Investigation in the field of Alzheimer's disease (AD), the commonest cause of dementia, has
been very active in recent years and it may be difficult for the clinician to keep up with all the …

Six-month walking program changes cognitive and ADL performance in patients with Alzheimer

M Venturelli, R Scarsini… - American Journal of …, 2011 - journals.sagepub.com
Motor inactivity is typical in the later stages of Alzheimer's disease although there is
evidence that physical exercise can reduce depression and enhance performance of daily …

[HTML][HTML] Statistical disease progression modeling in Alzheimer disease

LL Raket - Frontiers in big Data, 2020 - frontiersin.org
Background: The characterizing symptom of Alzheimer disease (AD) is cognitive
deterioration. While much recent work has focused on defining AD as a biological construct …

[HTML][HTML] Risk factors for late-life cognitive decline and variation with age and sex in the Sydney Memory and Ageing Study

DM Lipnicki, PS Sachdev, J Crawford, S Reppermund… - PloS one, 2013 - journals.plos.org
Introduction An aging population brings increasing burdens and costs to individuals and
society arising from late-life cognitive decline, the causes of which are unclear. We aimed to …

[HTML][HTML] Comparison between physical and cognitive treatment in patients with MIC and Alzheimer's disease

C Fonte, N Smania, A Pedrinolla, D Munari… - Aging (Albany …, 2019 - ncbi.nlm.nih.gov
Cognitive and physical activity treatments (CT and PT) are two non-pharmacological
approaches frequently used in patients with Mild Cognitive Impairment (MCI) and …

Modifiable, non-modifiable, and clinical factors associated with progression of Alzheimer's disease

DA Loeffler - Journal of Alzheimer's Disease, 2021 - content.iospress.com
There is an extensive literature relating to factors associated with the development of
Alzheimer's disease (AD), but less is known about factors which may contribute to its …

Accumulation of network redundancy marks the early stage of Alzheimer's disease

M Ghanbari, G Li, LM Hsu, PT Yap - Human Brain Mapping, 2023 - Wiley Online Library
Brain wiring redundancy counteracts aging‐related cognitive decline by reserving additional
communication channels as a neuroprotective mechanism. Such a mechanism plays a …

Prevalence, semiology, and risk factors of epilepsy in Alzheimer's disease: an ambulatory EEG study

A Horváth, A Szűcs, Z Hidasi, G Csukly… - Journal of …, 2018 - content.iospress.com
Background: Alzheimer's disease (AD) is the primary cause of cognitive decline. A growing
body of evidence suggests that AD patients have a higher risk to develop epileptic seizures; …

Effects of diabetes mellitus on cognitive decline in patients with Alzheimer disease: a systematic review

J Li, M Cesari, F Liu, B Dong, B Vellas - Canadian journal of diabetes, 2017 - Elsevier
Basic and clinical research support a link between diabetes mellitus and Alzheimer disease
(AD). However, the relationship with AD progression is unclear. This review focuses on the …